Utility of CHA2DS2-VASc Score to Predict 1 Mid-Term Clinical Outcomes in Hemodialysis Patients
American Journal of Nephrology Volume 53 Issue 2-3
Page 169-175
published_at 2022-03-08
アクセス数 : 76 件
ダウンロード数 : 38 件
今月のアクセス数 : 1 件
今月のダウンロード数 : 2 件
この文献の参照には次のURLをご利用ください : https://ir.lib.hiroshima-u.ac.jp/00054596
File |
AmJNeph_53_169.pdf
2.41 MB
種類 :
fulltext
|
Title ( eng ) |
Utility of CHA2DS2-VASc Score to Predict 1 Mid-Term Clinical Outcomes in Hemodialysis Patients
|
Creator |
Okubo Aiko
Nishizawa Yoshiko
Yamashita Kazuomi
Shigemoto Kenichiro
Mizuiri Sonoo
Usui Koji
Arita Michiko
Naito Takayuki
Masaki Takao
|
Source Title |
American Journal of Nephrology
|
Volume | 53 |
Issue | 2-3 |
Start Page | 169 |
End Page | 175 |
Abstract |
Background. The CHA2DS2-VASc score has been widely used to predict stroke in patients with atrial fibrillation (AF). Recently, it was reported that the CHA2DS2-VASc score helps predict cardiovascular disease (CVD) or all-cause mortality in patients with or without AF. However, few reports have examined the association between this score and mortality in hemodialysis patients.
Methods. We analyzed 557 consecutive patients who initiated hemodialysis at our facilities between February 2005 and October 2017. The CHA2DS2-VASc score was calculated at the time of initiation of hemodialysis. Patients were then categorized into three groups according to their CHA2DS2-VASc scores: 0–1 (low), 2–3 (intermediate), and 4–9 (high). Multivariate Cox proportional hazards analysis was used to assess independent risk factors for 3-year all-cause mortality. Results. During the 3-year follow-up period, 153 (27.5%) patients died (cardiovascular death: n=88). According to multivariate analysis, serum albumin (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.43–0.85, P=0.003), creatinine (HR 0.91, 95% CI 0.84–0.99, P=0.049), and CHA2DS2-VASc score (HR 1.33, 95% CI 1.20–1.46, P<0.001) were associated with 3-year all-cause mortality. Compared with patients in the low CHA2DS2-VASc score group, those in the intermediate and high score groups had a higher risk for all-cause and CVD mortality (all-cause mortality: 50 HR 1.77, 95% CI 1.23–2.55, P=0.002 and HR 2.94, 95% CI 1.90–4.53, P<0.001, respectively; CVD mortality: HR 1.82, 95% CI 1.27–2.59, P=0.001 and HR 2.85, 95% CI 1.88–4.31, P<0.001, respectively). Conclusion. The CHA2DS2-VASc score is a valuable predictor of 3-year all-cause and CVD mortality in incident hemodialysis patients. |
Keywords |
CHA2DS2-VASc score
Mortality
Hemodialysis
|
Language |
eng
|
Resource Type | journal article |
Publisher |
Karger
|
Date of Issued | 2022-03-08 |
Rights |
© 2022 S. Karger AG, Basel. The final, published version of this article is available at https://karger.com/?doi=10.1159/000522225.
This is not the published version. Please cite only the published version.
この論文は出版社版ではありません。引用の際には出版社版をご確認、ご利用ください。
|
Publish Type | Accepted Manuscript |
Access Rights | open access |
Source Identifier |
[DOI] https://doi.org/10.1159/000522225
isVersionOf
|